

Partners for *Life*[™]



As Partners for Life, Fujifilm Life Sciences companies are committed to building enduring, trust-based relationships that span the entire drug development life cycle.

With unique experience under our life sciences umbrella, we are a trusted, single-source partner supporting therapeutics from discovery to commercial supply to tackle devastating diseases and improve patient lives. We provide our customers the innovation, speed, and scalability needed across every stage of the therapeutics journey to provide medicines to the millions of patients lacking sufficient treatment options.



2

We're committed to building enduring relationships that span the entire drug development life cycle through our diverse portfolio of products and services including:

Biopharmaceutical CDMO

Cell culture solutions

iPS cell services and research products

CRO services

Lab / diagnostic reagents and specialty chemicals

Advanced R&D

This portfolio enables us to support breakthroughs and accelerate the creation of life-changing treatments that improve patient outcomes worldwide in these life science areas.


It provides us the opportunity, through collaboration, expertise, and consistency, to be Partners for Life.

Building trust through our Partners for Life Strategy

There are three main pillars that help define how we serve customers and patients as Partners for Life:



Put Our People First — We're built for people. By ensuring every employee finds meaning in their daily job, we release true passion and spark, something you recognize and feel when working with us.



Transformative Science and Innovation — We power innovation through our ability to fuse deep bioproduction expertise — spanning cells, cell culture solutions, and process development — with Fujifilm's core strengths in AI and sensing.




Unprecedented Delivery — We operate a global network of manufacturing and technology centers across locations in the US, UK, Denmark, and Japan — delivering products where and when partners need them.

Our reach matches your ambitions

As Partners for Life, we are committed to delivering for our partners through a centralized supply chain that serves all major markets worldwide. Our facilities in the United States, Europe, and Japan give our partners global flexibility and reach, regardless of their locations or geopolitical concerns. Flexibility, resiliency, and agility through our global footprint enable us to serve our partner needs.

4





End-to-end CDMO services

We offer world-leading contract development and manufacturing organization (CDMO) services for biologics, vaccines, and advanced therapies with production facilities in the United States, Europe, and Japan.

Our end-to-end CDMO services are designed to support the development of biopharmaceuticals from preclinical to commercial supply. Our integrated solutions combine scientific expertise, regulatory insights, and advanced manufacturing capabilities to accelerate timelines, ensure compliance, and drive success.

As trusted Partners for Life, we give our customers everything they need to develop and supply treatments and therapies effectively and efficiently to improve patients' lives.

- **Microbial, mammalian, and host/virus systems:** Comprehensive process development, analytical, and manufacturing services across small-, mid-, and large-scale for a variety of expression systems.
- **Cell and gene therapy CDMO support:** Offering innovative development and manufacturing services from discovery to commercial market supply across a variety of therapeutic cell and viral vector types.
- **CDMO services for LNP/Liposome/mRNA:** Offering fully integrated CDMO services tailored to the development and manufacturing of lipid nanoparticles (LNPs), liposomes, and mRNA-based therapeutics.
- **Antibody-drug conjugates (ADCs):** Planning to provide integrated services for ADCs from 2027.

New facilities

We provide a global manufacturing network with state-of-the-art facilities covering large- to small-scale production and uniform processes.



Large Scale

Small/Mid Scale

Holly Springs, NC, USA



20,000 L Bioreactors

Toyama, Japan



2,000 L, 5,000 L Bioreactors

Hillerød, Denmark



Billingham, UK



Making the standard extraordinary

Kojo — has a dual meaning in Japanese: “factory” and “improvement.”

X — represents both the power of being location-agnostic and the exponential impact we seek to transform the industry.

Taken together, **kojoX™** is how we’re building a global CDMO network across scales, technologies, and locations with a harmonization level that has never been seen before in the pharmaceutical industry.



Flexibility



Scalability



Speed

Rather than building each site as a unique facility, kojoX™ introduces a standardized approach to facility design and process operations. This gives us true supply agility, a flexibility that allows us to adapt to new products quickly, while giving us the ability to transfer products to and from anywhere in our global network.

This plug-and-play harmonization enables seamless technology transfer, faster regulatory filings, and more flexible capacity deployment. This in turn reduces the time and complexity traditionally associated with scaling biopharmaceutical manufacturing, allowing us to deliver important medicines to patients around the world more quickly.



Life Sciences Solutions

Our comprehensive portfolio supports scientists, researchers, and institutions at the forefront of discovery with cutting-edge research tools. As trusted Partners for Life, we bring those discoveries to life with the raw materials, cell culture solutions, and services to support the manufacturing of biologics and vaccines.

- **Cell culture solutions:** We offer a diverse portfolio of advanced solutions, including specialized media, custom media development and manufacturing, and technologies for bioprocessing targeted to meet the evolving demands of the biopharmaceutical, vaccine, and cell therapy industries.
- **Laboratory reagents:** Our high-purity reagents play a critical role in enabling accurate, reproducible results across a wide range of applications, from molecular biology and analytical chemistry to cell culture and clinical testing.
- **iPS cell-derived tools:** Our iPS-derived off-the-shelf cell types (iCell® products) offer disease-relevant, human in vitro systems for drug and toxicity screening, disease modeling, and also serve as quality control and release testing platforms.

8



Advanced Therapies

We are your Partners for Life in bringing advanced cell therapies to patients. With end-to-end cell therapy, we provide CDMO solutions from pre-clinical development to commercial production. We offer research and manufacturing materials including iPSC cell lines, cell culture solutions, reagents, cytokines, and small molecules.


- **Cell therapy:** We advance your cell therapies from lab to commercial scale leveraging our cell therapy expertise.
- **iPS cell therapy:** Our 14 fully consented, Master File enabled GMP iPSC lines can be licensed, or used in the context of our development and manufacturing services for allogeneic tissue repair approaches.
- **Gene therapy:** Creating effective, scalable manufacturing strategies for our partners ensures that we provide a customized service on your path to commercialization.
- **Vaccines:** With more than 30 years' experience in microbial and virus-based cGMP biomanufacturing, we provide the technical expertise, process development, capacity availability, and global network that is critical for your product to reach its final delivery.
- **LNP:** LNP/liposome contract services support the commercialization of nanoparticle-based pharmaceuticals, leveraging our chemistry expertise.

CRO Services

We are expanding our drug discovery contract research organization (CRO) services by utilizing cutting-edge technologies such as iPSC-derived cell assays and AI-based drug design. Specialty areas include:

- iPSC platform
- Antibody discovery
- AI for drug discovery
- Peptide discovery
- Infectious diseases
- Drug efficacy and analysis services





An engine of innovation: BSEL

Established in 2019, the Bio Science & Engineering Laboratories (BSEL) serve as an internal innovation engine that brings together employees from across Fujifilm’s businesses to continue our decades-long legacy of collaboration and innovation. This multidisciplinary hub houses more than 200 researchers — including over 50 PhD scientists and engineers — where new ideas and novel technologies are developed that strengthen Fujifilm’s scientific foundation and accelerate biomanufacturing innovation across our global network.

Funded projects through BSEL focus on three core objectives:

Strengthening the foundation of existing capabilities

Improving process efficiency

Driving product development to address emerging industry needs

While many of these projects are still in early stages, they are already producing meaningful results. Examples include:

Next-generation iPS cell development: Advancing strategies for improved cell differentiation and scalability.

Single-cell RNA sequencing for T cell differentiation under GMP conditions: Enabling deeper insight into cell therapy processes for more consistent manufacturing outcomes.

Together, such efforts illustrate how BSEL bridges scientific discovery and practical implementation — driving innovation not only for Fujifilm but also for partners and customers across the full development spectrum.

Bioprocessing innovation

We have process and development scientists within each life science company (FUJIFILM Biosciences, FUJIFILM Cellular Dynamics, Inc, FUJIFILM Wako Pure Chemical, FUJIFILM Toyama Chemical) and 500+ process scientists across FUJIFILM Biotechnologies' CDMO sites (USA, United Kingdom, and Denmark).


Positioned closer to our customers, these sites drive bioprocessing improvements and innovate alongside our customers to address challenges in real time. This approach not only advances manufacturing innovation but also accelerates the delivery of solutions where they matter most.

ApolloX[™] - Mammalian Expression System

The scalable ApolloX[™] platform is designed for quality and speed of delivery of monoclonal antibodies (mAbs) and a diverse range of CHO-expressed molecules, including bispecific antibody formats, Fc-fusion proteins, and non-Fc containing recombinant proteins.

MaruX[™] - Setting the Standard for End-to-End Continuous Biomanufacturing

The MaruX[™] platform radically reimagines continuous manufacturing of recombinant proteins by automating and integrating both upstream and downstream processes. MaruX[™], which offers single-use perfusion bioreactors for high-density cultures at the 500 L to 2,000 L scale, uses an intensified, consecutive-batch end-to-end processing approach that boasts advanced buffer management, streamlined scale-up and scale-out capabilities, improved raw material efficiency and costs, while delivering unparalleled quality for our partners and patients.





Paveway PLUS™: Accelerating Microbial Biotherapeutic Development

Paveway PLUS™ is our proprietary microbial expression and strain development solution that has been developed for E. coli fermentation across early discovery, pre-clinical, and scale-up phases. Modular, high-throughput workflows enable rapid lead-strain selection in as little as four weeks, with product-quality metrics integrated throughout the process.

ShunzymeX™

ShunzymeX™ is our precision purification technology designed to simplify downstream processing of complex biologics. The technology addresses some of the inherent challenges due to diversity of biologics, including variability in size and sequence.

Oceo Rover™

The Oceo Rover™ is the first fully automated, on-demand single-use hydration system for media feeds and buffers. It replaces traditional powder hydration in stirred tanks with a single, programmable unit that delivers fast, consistent, ready-to-use solutions for both upstream and downstream processes with unmatched flexibility and scalability.

iPSC-Derived Cells

iCell® Catalog and Custom Development

Developed by FUJIFILM Cellular Dynamics, iCell® catalog products provide off-the-shelf cell models for in vitro research, including neuronal, glial, cardiac, intestinal, hematopoietic cells, and more. In addition, custom cell model development is supported through established differentiation protocols and gene-editing capabilities to generate cell types not currently available and enable access to partner iPSC banks representing diverse disease states and apparently healthy donors.

iPSC Complex Models

Recent FUJIFILM Cellular Dynamics product launches include multicell-type complex models designed to better recapitulate human physiology. These offerings include the iCell® Blood-Brain Barrier for evaluating CNS penetration, as well as a neuromuscular junction model to support advanced neurological research applications.

Cell Sterility Testing


RiboNAT™ Rapid Sterility Test

FUJIFILM Wako Pure Chemical's RiboNAT™ Rapid Sterility Test reduces the time required to confirm product sterility to approximately seven hours (within one day, down from up to 14 days lead time), enabling faster and safer delivery of life-saving therapies.

AI and Biomechanics

Bio AI Vision

Combining biomechanics and machine learning, we are developing AI-powered capabilities to predict production outcomes based on culture conditions. During production, this technology helps minimize variation in quality and yield from batch-to-batch and site-to-site, facilitating smooth product transfer between sites.



FUJIFILM Biotechnologies

FUJIFILM Biotechnologies serves global partners seeking CDMO services from preclinical to clinical to approval, and commercialization across all modalities and scales.

We work in strategic partnership with biopharmaceutical and biotech companies to develop and manufacture the latest in biologics, advanced therapies, and vaccines. Our solutions bridge the gap between drug discovery and commercial supply — helping to bring life-impacting treatments to patients every day.

FUJIFILM Biosciences

With a foundation in cell culture that dates back to 1970, we are a full spectrum supplier to the life sciences market, providing products and services that assist customers in advancing healthcare initiatives. With an expanding portfolio of supported applications including life science and discovery research, cell and gene therapy, as well as the large-scale production of biotherapeutics and vaccines, we are trusted by researchers and manufacturers worldwide.

FUJIFILM Cellular Dynamics

Our technology enables the creation of human induced pluripotent stem cells (iPSCs) from anyone, starting with a standard blood draw. Meanwhile, our proprietary manufacturing system and cGMP capabilities enable large-scale production of a range of cell types with high reproducibility for research use and therapeutic use, including cardiac, neural, hematopoietic, hepatic, and other cells.

FUJIFILM Toyama Chemical

We are focused on the CDMO business for new modalities and the discovery support CRO business. We license our proprietary ionizable lipids designed for in vivo/ex vivo nucleic acid delivery with enhanced bioavailability. We also offer services to accelerate client drug discovery / development processes as well as our work to develop medicines for drug-resistant bacterial infections. FUJIFILM Pharmaceuticals USA is a marketing partner of FUJIFILM Toyama Chemical.

FUJIFILM Wako Pure Chemical

We provide highly functional and high-quality laboratory chemicals, specialty chemicals, and clinical diagnostic reagents as well as fine chemicals for pharmaceutical and biopharmaceutical production. Solutions also include contract research services and distribution services worldwide to address a range of customer needs.



Fujifilm Group

Founded over 90 years ago, Fujifilm is one of the world's leading technology companies. Our history as a photographic film manufacturing company, combined with a legacy of innovation, make Fujifilm one of the most respected brands across a diverse range of business areas.

We integrate cutting-edge production-control and quality-control strategies, inspired by our heritage in photographic technology, with a commitment to sustainable growth as outlined in Fujifilm's Sustainable Value Plan 2030.

In the life sciences field, Fujifilm's Partners for Life strategy inspires us to be the leading and most trusted partner as we support our clients in the discovery, development, manufacture, and commercialization of new therapies.




Giving our world more smiles

- Since our foundation, the Fujifilm Group has transformed into a global innovator in healthcare, electronics, business innovation, and imaging.
- We have created value from innovation by bringing diverse ideas, unique capabilities, and extraordinary people — who achieve their aspirations and give smiles to the world — together.
- This is at the heart of the Fujifilm Group's Purpose, "Giving our world more smiles."
- Our Group Purpose guides and unifies all of our talented people across all of our companies.

At Fujifilm, innovation is what we do. Smiles are why we do it.





Scan the QR code
to learn more.



Fujifilm Life Sciences
Companies

Partners for *Life*[™]

